Development of a sublingual mucosal immunization technology platform for needle-free vaccination
The construction of hybridomas producing monoclonal antibodies for new, more specific diagnostic kits for the detection of colon cancer and some air allergens.
For some patients, voice production after laryngectomy is impossible.For others voice quality is unpredictable or poor to enable high-quality voice production for those patients, a voice-producing shunt prosthesis will be developed.
Development of new monoclonal antibodies against signal transducer and transcription activator "stati" protein and its endogenous inhibitor "socs3" protein. Construction of kit for detection of hla-g antigens.
Using well-characterized antibodies to form the basis for the development of diagnostic kits to monitor neurodegenrative processes.
Development and pre-clinical testing of at least two compounds for the effective treatment of migraines.
Development of a direct and effective method of directly imaging the structural degradation of peripheral neurones as encountered in various types of neuropathies.
Efficient control strategies against phytoplasma vectoring psyllids will be established by the help of molecular markers to study their life cycle, by determining the transmission parameters and by developing disturbation strategies.
Production of antibodies against novel gene products(proteins) is essential, but there are often obstacles to studying brain function or disease. Commercial availability of sets of antibodies will be useful to many brain research facilities.
Signalling proteins will be prepared using recombinant techniques and used for making poly and monoclonal antibodies. Antibodies to cell surface receptors will be labelled using modern fluorochromes. These products will be marketed by the czech biotech company exbio.